Evidence map›Paper›PMID 36993701›Full record

ArticlebioRxiv : the preprint server for biology2023

Antiviral activities of two nucleos(t)ide analogs against vaccinia and mpox viruses in primary human fibroblasts.

Lara Dsouza, Anil Pant, Samuel Offei, Lalita Priyamvada, Blake Pope, Panayampalli S Satheshkumar, Zhengqiang Wang, Zhilong Yang

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Lara DsouzaDepartment of Veterinary Pathobiology, School of Veterinary Medicine & Biomedical Sciences, Texas A&M University, College Station, Texas, USA.
Anil PantDepartment of Veterinary Pathobiology, School of Veterinary Medicine & Biomedical Sciences, Texas A&M University, College Station, Texas, USA.
Samuel OffeiCenter for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA.
Lalita PriyamvadaPoxvirus and Rabies Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Blake PopeDepartment of Veterinary Pathobiology, School of Veterinary Medicine & Biomedical Sciences, Texas A&M University, College Station, Texas, USA.
Panayampalli S SatheshkumarPoxvirus and Rabies Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Zhengqiang WangCenter for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA.
Zhilong YangDepartment of Veterinary Pathobiology, School of Veterinary Medicine & Biomedical Sciences, Texas A&M University, College Station, Texas, USA.
Texas A&M University · USCenters for Disease Control and Prevention · USUniversity of Minnesota · US

Funding

Mechanisms regulating poxvirus post-replicative protein synthesisR01AI143709 · NIAID · TEXAS A&M AGRILIFE RESEARCH · PI YANG, ZHILONG · 2019 to 2023
$1.9M
Selective translation conferred by the poly(A) leader of vaccinia virus mRNAsR21AI128406 · NIAID · KANSAS STATE UNIVERSITY · PI YANG, ZHILONG · 2017 to 2018
$413k
NIAID NIH HHS R01 AI143709NIAID NIH HHS R21 AI128406
6 · The paper itself

Abstract

Many poxviruses are significant human and animal pathogens, including viruses that cause smallpox and mpox. Identification of inhibitors of poxvirus replication is critical for drug development to manage poxvirus threats. Here we tested two compounds, nucleoside trifluridine and nucleotide adefovir dipivoxil, for antiviral activities against vaccinia virus (VACV) and mpox virus (MPXV) in physiologically relevant primary human fibroblasts. Both trifluridine and adefovir dipivoxil potently inhibited replication of VACV and MPXV (MA001 2022 isolate) in a plaque assay. Upon further characterization, they both conferred high potency in inhibiting VACV replication with half maximal effective concentrations (EC

Identifiers

PMID36993701
PMCPMC10055413
OpenAlexW4360868838

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.